Short answer
West Pharmaceutical Services (WST) filed its Q3 2025 10-Q quarterly report on Oct 23, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $805M (up 7.7% year over year) with net income of $140M.
Q3 2025 key financials · XBRL
- Revenue
- $805M
- +7.7% YoY · +5.0% QoQ
- Net income
- $140M
- +2.9% YoY · +6.2% QoQ
- Operating margin
- 20.8%
- Gross margin
- 36.6%
- EPS (diluted)
- $1.92
- +3.8% YoY · +5.5% QoQ
Source: XBRL data from the West Pharmaceutical Services (WST) Q3 2025 10-Q on SEC EDGAR. USD.
West Pharmaceutical Services Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $805M, up 7.7% YoY ($57.7M increase) for Q3 2025; Proprietary Products $647.5M (+7.7%), Contract-Manufactured Products $157.1M (+8.0%)
- Operating margin 20.8% vs 21.6% YoY Q3 2025 (down 0.8 pts); adjusted operating margin 21.1% vs 21.5%; gross margin 36.6% vs 35.4% (up 1.2 pts)
- Best segment: Proprietary Products operating profit up 10.7% YoY Q3 2025 to $175.2M; worst segment: Contract-Manufactured Products operating profit slightly up 2.3% YoY Q3 2025 to $22.3M but down 4.5% YTD
- Cash and equivalents rose to $628.5M (Sept 30, 2025) from $484.6M (Dec 31, 2024); operating cash flow $503.7M for 9 months ended Sept 30, 2025, up $40.4M YoY; share repurchases $134M in 9 months 2025 vs higher in 2024
- Management expects no material impact from tariffs or geopolitical risks; operating profit growth continues but corporate expenses and restructuring charges increased; outlook cautious on cost pressures and maintaining production efficiency
Risk Factors
- Continued COVID-19 impact on supply chain and customer demand remains key operational risk
- Exposure to foreign currency fluctuations affecting reported results due to international sales
- New product development and regulatory approval delays could impact near-term competitive position
- Ongoing legal proceedings related to patent disputes involving product portfolio risks compliance
- Debt maturities concentrated in 2026 require cash flow management to mitigate financial liquidity risk
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other West Pharmaceutical Services quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.